logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

SABCS 2019 – Adding S-1 to endocrine treatment improves survival in HR+, HER2− breast cancer

Japanese phase 3 POTENT trial reported 39% reduction in disease recurrence.